BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 15606446)

  • 1. A meta-analysis of clinical trials of paclitaxel- and sirolimus-eluting stents in patients with obstructive coronary artery disease.
    Shafiq N; Malhotra S; Pandhi P; Grover A; Uboweja A
    Br J Clin Pharmacol; 2005 Jan; 59(1):94-101. PubMed ID: 15606446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A meta-analysis of trials comparing Cypher and Taxus stents in patients with obstructive coronary artery disease.
    Sidhu S; Shafiq N; Malhotra S; Pandhi P; Grover A
    Br J Clin Pharmacol; 2006 Jun; 61(6):720-6. PubMed ID: 16722835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial.
    Morice MC; Colombo A; Meier B; Serruys P; Tamburino C; Guagliumi G; Sousa E; Stoll HP;
    JAMA; 2006 Feb; 295(8):895-904. PubMed ID: 16493102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents.
    Babapulle MN; Joseph L; Bélisle P; Brophy JM; Eisenberg MJ
    Lancet; 2004 Aug 14-20; 364(9434):583-91. PubMed ID: 15313358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
    Stone GW; Moses JW; Ellis SG; Schofer J; Dawkins KD; Morice MC; Colombo A; Schampaert E; Grube E; Kirtane AJ; Cutlip DE; Fahy M; Pocock SJ; Mehran R; Leon MB
    N Engl J Med; 2007 Mar; 356(10):998-1008. PubMed ID: 17296824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Catheter-based delivery of fluid paclitaxel for prevention of restenosis in native coronary artery lesions after stent implantation.
    Herdeg C; Göhring-Frischholz K; Haase KK; Geisler T; Zürn C; Hartmann U; Wöhrle J; Nusser T; Dippon J; May AE; Gawaz M
    Circ Cardiovasc Interv; 2009 Aug; 2(4):294-301. PubMed ID: 20031731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization.
    Windecker S; Remondino A; Eberli FR; Jüni P; Räber L; Wenaweser P; Togni M; Billinger M; Tüller D; Seiler C; Roffi M; Corti R; Sütsch G; Maier W; Lüscher T; Hess OM; Egger M; Meier B
    N Engl J Med; 2005 Aug; 353(7):653-62. PubMed ID: 16105989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial.
    Lemos PA; Moulin B; Perin MA; Oliveira LA; Arruda JA; Lima VC; Lima AA; Caramori PR; Medeiros CR; Barbosa MR; Brito FS; Ribeiro EE; Martinez EE;
    Catheter Cardiovasc Interv; 2009 Nov; 74(5):665-73. PubMed ID: 19670303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis.
    Nordmann AJ; Briel M; Bucher HC
    Eur Heart J; 2006 Dec; 27(23):2784-814. PubMed ID: 17020889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug eluting stents: an updated meta-analysis of randomised controlled trials.
    Roiron C; Sanchez P; Bouzamondo A; Lechat P; Montalescot G
    Heart; 2006 May; 92(5):641-9. PubMed ID: 16216853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of sirolimus-eluting stents on outcome in diabetic patients: a SIRIUS (SIRolImUS-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy.
    Moussa I; Leon MB; Baim DS; O'Neill WW; Popma JJ; Buchbinder M; Midwall J; Simonton CA; Keim E; Wang P; Kuntz RE; Moses JW
    Circulation; 2004 May; 109(19):2273-8. PubMed ID: 15123524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Sirolimus-eluting vs paclitaxel-eluting stents -- the trials confirm differences in clinical outcome].
    Gil RJ
    Kardiol Pol; 2005 Nov; 63(5):574-6; discussion 577. PubMed ID: 16362868
    [No Abstract]   [Full Text] [Related]  

  • 13. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sirolimus-eluting stents inhibit neointimal hyperplasia in diabetic patients. Insights from the RAVEL Trial.
    Abizaid A; Costa MA; Blanchard D; Albertal M; Eltchaninoff H; Guagliumi G; Geert-Jan L; Abizaid AS; Sousa AG; Wuelfert E; Wietze L; Sousa JE; Serruys PW; Morice MC;
    Eur Heart J; 2004 Jan; 25(2):107-12. PubMed ID: 14720526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zotarolimus-eluting stent versus sirolimus-eluting and paclitaxel-eluting stents for percutaneous coronary intervention: a meta-analysis of randomized trials.
    Sethi A; Bahekar A; Bhuriya R; Bajaj A; Singh PP; Arora R; Khosla S
    Arch Cardiovasc Dis; 2012 Nov; 105(11):544-56. PubMed ID: 23177483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stent thrombosis in randomized clinical trials of drug-eluting stents.
    Mauri L; Hsieh WH; Massaro JM; Ho KK; D'Agostino R; Cutlip DE
    N Engl J Med; 2007 Mar; 356(10):1020-9. PubMed ID: 17296821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials.
    Stettler C; Allemann S; Egger M; Windecker S; Meier B; Diem P
    Heart; 2006 May; 92(5):650-7. PubMed ID: 16251229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of left anterior descending coronary artery disease with sirolimus-eluting stents.
    Sawhney N; Moses JW; Leon MB; Kuntz RE; Popma JJ; Bachinsky W; Bass T; DeMaio S; Fry E; Holmes DR; Teirstein PS
    Circulation; 2004 Jul; 110(4):374-9. PubMed ID: 15249503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of drug-eluting stents in the coronary artery in ST-elevation myocardial infarction at a single high-volume medical center.
    Bose R; Gupta G; Grayburn PA; Laible EA; Kang MJ; Choi JW
    Am J Cardiol; 2007 Sep; 100(6):949-52. PubMed ID: 17826375
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-eluting coronary stents: many meta-analyses, little benefit.
    Prescrire Int; 2009 Apr; 18(100):70-4. PubMed ID: 19585727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.